BiotechTube

Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome With Constipation

Conditions

Irritable Bowel Syndrome With Constipation, Functional Constipation

Trial Timeline

Nov 19, 2019 → Jun 5, 2025

NCT ID
NCT04166058

About Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) is a phase 3 stage product being developed by AbbVie for Irritable Bowel Syndrome With Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT04166058. Target conditions include Irritable Bowel Syndrome With Constipation, Functional Constipation.

What happened to similar drugs?

7 of 20 similar drugs in Irritable Bowel Syndrome With Constipation were approved

Approved (7) Terminated (1) Active (13)
✅Ramosetron + PlaceboAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅Bacillus clausii + MetronidazoleSanofiApproved
✅Iberogast® and Iberogast® NBayerApproved
✅LinaclotideIronwood PharmaceuticalsApproved
✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04166058Phase 3Completed

Competing Products

20 competing products in Irritable Bowel Syndrome With Constipation

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
YM060 + PlaceboAstellas PharmaPhase 3
40
Ramosetron + PlaceboAstellas PharmaApproved
43
Ramosetron + PlaceboAstellas PharmaApproved
43
YM060Astellas PharmaPhase 3
40
YM060 + placeboAstellas PharmaPhase 2
35
YM060Astellas PharmaPhase 3
40
linaclotide + PlaceboAstellas PharmaPhase 3
40
RamosetronAstellas PharmaPre-clinical
26
YM060Astellas PharmaPhase 2
35
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
27
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
duloxetineEli LillyApproved
43
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
47
Eluxadoline + PlaceboAbbViePhase 2
42
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisPre-clinical
26
DNK333NovartisPhase 2
35
SMS995 + PlaceboNovartisPhase 1
29
DNK333 + PlaceboNovartisPhase 2
35